Jennison Associates LLC Altimmune, Inc. Transaction History

Jennison Associates LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$8.74 - $16.45 $6.53 Million - $12.3 Million	747,283 Added 411.66%	928,813 $15.3 Million
Q3 2022 Nov 01, 2022	BUY	$10.67 - $22.41 $768,944 - $1.61 Million	72,066 Added 65.84%	181,530 $2.32 Million
Q2 2022 Aug 02, 2022	BUY	$3.94 - $11.77 $431,288 - $1.29 Million	109,464 New	109,464 $1.28 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.